|
| |
BioPortfolio's Approved Drugs DatabaseCancidasCaspofungin AcetateDownload PDF containing detailed information.
Press Releases About Cancidas:
|
 |
| FDA Clears Caspofungin (Cancidas(R)) Susceptibility Testing for TREK Sensititre(R) YeastOne(R) in Vitro Diagnostics (IVD) Product Line |
7th July, 2009 |
TREK Diagnostic Systems |
CLEVELAND, July 7 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has received
|
| New Survey forecasts over 70% revenue growth in systematic antifungal
|
1st July, 2004 |
Datamonitor |
New
Survey forecasts over 70% revenue growth in systematic antifungal market over
the next decade
Pfizer, Merck
& Co. and Fujisawa best positioned
London -
According to a new report* from
|
| The next Generation Antifungals: Triazoles vs Peptides |
1st January, 1970 |
Bioseeker |
BioSeeker
report "The next Generation Antifungals: Triazoles vs Peptides"
According to
the Antifungal Work Group at NIH there
|
| Fungal infections: From specialty area to expanded population |
1st January, 1970 |
Datamonitor |
Fungal
infections: From specialty area to expanded population
According to
new research from Datamonitor, out of nine million patients at-risk, 1.2 million
|
This page has been viewed 16 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Cancidas across BioPortfolio, or for Cancidas Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|